UBS analyst Kevin Caliendo raised the firm’s price target on Cardinal Health to $91 from $78 and keeps a Buy rating on the shares as part of a broader research note on pharma distributors. The analyst contends that Pharma distribution is a relative safe haven while noting "stable" Rx trends and positive channel checks around brand and generic drug inflation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAH: